Pfizer, BioNTech lose UK appeal to Moderna in Covid-19 vaccine patent fight
The Appeals Court in London upheld an earlier UK court decision in the long-running battle between the global pharma firms.
It found that one of the European patents held by Moderna was invalid, but that a second one had been broken by Pfizer and its German partner BioNTech.
"The judge made no error of law or principle" in the ruling handed down in July 2024, the Appeal Court judges wrote Friday, dismissing the appeal brought by the two companies.
Pfizer quickly said it will appeal Friday's ruling to Britain's Supreme Court.
"Today's UK Court of Appeal's decision does not change our unwavering stance that this patent is invalid," Pfizer said in a statement. "This decision has no immediate impact on Pfizer and BioNTech."
Pfizer and BioNTech had argued that both the patents cited by Moderna were invalid, and neither had been infringed.
Friday's decision could have wide implications for other cases involving the huge pharma companies in the United States, Germany, Belgium, the Netherlands and Ireland.
Moderna said in a statement it was pleased with Friday's ruling and would "continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology."
A UK court was told last year the firms had spent £19 million (US$25 million) fighting their legal battles.
In 2020, Pfizer and BioNTech's vaccine became the first ever mRNA vaccine approved for widespread use, and was swiftly deployed to combat the Covid pandemic.
Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases.
Traditional vaccines contain some form of the dead or inactivated target virus.
Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines.
In March, a German court in Duesseldorf also found Pfizer and BioNTech had violated a Moderna patent filed between 2010 to 2016 to make their vaccines.
It ordered they must provide estimates of how much they had profited from breaking the patent as well as provide "appropriate compensation."--AFP
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
7 minutes ago
- The Star
CIIE promotion event aims to boost China-Czech business ties
PRAGUE, Aug. 5 (Xinhua) -- An event promoting the China International Import Expo (CIIE) in the Czech Republic was held here on Tuesday, bringing together representatives from the Czech government, the business community, industry associations, and Chinese enterprises to explore new opportunities for boosting China-Czech economic and trade cooperation. Speaking at the event, Liu Haiyan, economic and commercial counselor at the Chinese Embassy in the Czech Republic, said the CIIE serves as an important platform for China to further open up to the world and offers a golden opportunity for enterprises around the globe to access the Chinese market. Through the CIIE, Czech companies can showcase their high-quality products and further enhance their brand recognition and market share, he said, adding that he hopes Czech entrepreneurs will take this year's CIIE as an opportunity to further explore the Chinese market. During the event, a representative from the CIIE Bureau gave a virtual presentation on the upcoming eighth CIIE, which will take place in Shanghai from Nov. 5 to 10. Richard Hlavaty, director of the Department of Non-European Countries at the Ministry of Industry and Trade, said at the event that the Czech Republic considers the CIIE as a key opportunity to present the country, its innovation and industrial tradition, but also as a strategic channel for deepening economic and trade relations with China. "I firmly believe that through initiatives like this, we can continue to expand our economic ties and deepen mutual understanding between our countries," he said. Frantisek Chaloupecky, vice president of the Confederation of Industry of the Czech Republic, one of the co-organizers of the event, said that the CIIE provides an important platform for Czech companies, enabling them not only to showcase their products but also to establish business connections in the Chinese market. According to the organizers, 17 Czech exhibitors participated in last year's CIIE, primarily showcasing products in the food and beverage industries as well as the handicraft sector.
The Star
2 hours ago
- The Star
Pfizer reports strong Q2 revenue
NEW YORK, Aug. 5 (Xinhua) -- U.S. pharmaceutical company Pfizer announced its second-quarter earnings on Tuesday, reporting a 10 percent year over year operational growth. The financial results posted by the New York-headquartered company represent revenue of 14.7 billion U.S. dollars or 0.51 dollars of earnings per share. In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of 2.80 dollars to 3.00 dollars. The company maintained its annual revenue projection of 61 billion to 64 billion dollars, reflecting confidence in its underlying business performance. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," Pfizer Chairman and CEO Albert Bourla said in a statement. Pfizer's strong performance came amid mounting policy pressures from the White House. U.S. President Donald Trump has recently sent letters to 17 pharmaceutical companies, including Pfizer, demanding that they cut prices on all existing medications for Medicaid patients to levels no higher than those in Europe. During Tuesday's earnings call, Bourla acknowledged that the company received the letter from the Trump administration. However, he declined to elaborate on the policy's specific impacts, although he emphasized that discussions with the administration have been "extremely productive." Pfizer's Q2 results were bolstered by rising sales in several key product categories. Its Vyndaqel line of cardiomyopathy treatments showed solid growth, and COVID-19-related products were major contributors.
The Star
2 hours ago
- The Star
EU halts 93-bln-euro tariffs on U.S. goods despite members' dissent
BRUSSELS, Aug. 5 (Xinhua) -- The European Commission on Tuesday formally suspended planned retaliatory tariffs on U.S. imports worth 93 billion euros (about 108 billion U.S. dollars), just days before they were due to take effect. The Commission's trade spokesperson, Olof Gill, said the decision was adopted under an emergency procedure and will require formal approval by a simple majority of member states within two weeks. The tariffs were scheduled to take effect on Aug. 7. "The Commission has today adopted necessary legal procedures to suspend the implementation of our European Union (EU) countermeasures," Gill told a press briefing in Brussels, adding that the regulation would be published in the EU's official journal later the same day. Ahead of this announcement, there has been mounting criticism from key member states, including France and Germany. German Vice Chancellor and Finance Minister Lars Klingbeil has expressed frustration at what he described as a "weak" negotiating stance by the EU during the trade talks with the United States. "I think we were too weak. We can't be satisfied with the result that was achieved," Klingbeil said, referring to the agreement reached late last month between European Commission President Ursula von der Leyen and U.S. President Donald Trump. Under the deal, most EU imports to the United States will face a 15-percent tariff, while the bloc has pledged to purchase more American energy products and increase investment in the U.S. market. Gill expressed surprise at Klingbeil's remarks, noting that member states had been "fully briefed" and had supported a negotiated outcome to avoid tariff escalation. The spokesperson said the suspension would remain in place for six months, during which implementation of the broader understanding would continue. If commitments are not met, Gill noted, the EU retains the right to reactivate its countermeasures. (1 euro = 1.16 dollar)
